



**hVIVO plc**  
**("hVIVO" or the "Company")**

**World Vaccine Congress Presentation**

hVIVO plc (AIM & Euronext: HVQ) (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that **Dr Andrew Catchpole, Chief Scientific Officer** will be delivering a presentation at the World Vaccine Congress, Washington D.C., United States. Full details of the presentation are included below:

**Title** *Challenge Studies - can the results be expected to mimic field trial data?*

**Date/Time** *Wednesday 5 April 2023, 17.10 (ET)*

The World Vaccine Congress will take place at the Walter E. Washington Convention Center in Washington D.C. between 3-6 April 2023. hVIVO will be at booth 813 during the congress for potential partnering discussions.

The World Vaccine Congress, organised by Terrapin, is the largest and most established meeting dedicated to vaccines and has run for 23 years. From basic research to commercial manufacture, the event covers the whole vaccine value chain, with hundreds of speakers and thousands of attendees from leading global vaccines developers, academia and policymakers.

More information about the event, including attendance, can be found [here](#).

To request meetings with hVIVO at the World Vaccine Congress, interested parties should register with Swapcard and use the following [link](#) or by emailing [bd@hvivo.com](mailto:bd@hvivo.com)

**Yamin 'Mo' Khan, Chief Executive Officer at hVIVO, said:** *"I am delighted that Andrew will be presenting at the largest vaccine event of the year amongst many other notable speakers, discussing the significant value of human challenge trial data. As the global leader in conducting human challenge trials to test vaccines and antivirals for infectious and respiratory diseases, we are looking forward to participating in roundtable discussions and sharing insights into how human challenge trials can accelerate the drug development process."*

**For further information please contact:**

<b>hVIVO plc</b> Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer	+44 (0) 20 7756 1300
<b>Liberum Capital (Nominated Adviser and Joint Broker)</b> Ben Cryer, Edward Mansfield, Phil Walker, Will King	+44 (0) 20 3100 2000
<b>finnCap plc (Joint Broker)</b> Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)	+44 (0) 20 7220 0500
<b>Davy (Euronext Growth Adviser and Joint Broker)</b> Anthony Farrell, Niall Gilchrist	+353 (0) 1 679 6363
<b>Walbrook PR (Financial PR &amp; IR)</b> Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson	+44 (0) 20 7933 8780 or <a href="mailto:hvivo@walbrookpr.com">hvivo@walbrookpr.com</a> +44 (0) 7796 794 663 / +44 (0) 7867 984 082 / +44 (0) 7747 515 393

## **Notes to Editors**

### **About hVIVO**

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Company has world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its [FluCamp](#) volunteer screening facilities in London and Manchester.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAGZGZFKRRGFZM